Opsens Inc. announced 510(k) clearance from the U.S. Food and Drug Administration to market its diastolic pressure algorithm ("dPR"). Coronary physiology has been in constant evolution with the expanded use of Fractional Flow Reserve and the support of strong clinical data and cardiology societies recommendations. More recently, the option for coronary physiology without hyperemia induced by the injection of heart stimulating drugs has emerged. Opsens has developed its proprietary diastolic pressure ratio (dPR) to meet this need. Non-Hyperemic Pressure Resting indices, such as Opsens' dPR, are beneficial for some patients as they reduce procedure time, costs and discomfort.